Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-02-2008 | Cornea

Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

Authors: Felix Bock, Yanyan König, Friedrich Kruse, Martin Baier, Claus Cursiefen

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2008

Abstract

Background

To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. Design: interventional case series involving five patients (age: 42 ± 14 years).

Methods

Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 ± 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).

Results

Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 ± 28%; 13–75%).

Conclusions

Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.

Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162–164PubMedCrossRef

Bock F, Onderka J, Dietrich T, Dietrich T, Bachmann B, Kruse FE, Cursiefen C (2007) Bevacizumab is a potent inhibitor of inflammatory angiogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci 48:2545–2552PubMedCrossRef

Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336–344PubMedCrossRef

Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249PubMedCrossRef

Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of VEGF, TGFα and TGFβ₁ in human corneas with neovascularization. Cornea 19:526–533PubMedCrossRef

Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101–106PubMedCrossRef

Cursiefen C, Maruyama K, Liu Y, Chen L, Jackson D, Wiegand S, Dana MR, Streilein JW (2004) Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666–2673PubMedCrossRef

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Streilein JW, Dana MR (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 103:11405–11410PubMedCrossRef

Manzano R, Peyman G, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91:804–807PubMedCrossRef

10.

Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579PubMedCrossRef

11.

Kuhlmann A, Amann K, Schlötzer-Schrehardt U, Kruse FE, Cursiefen C (2005) Endothelin-1 and Eta/Etb-receptor protein and mRNA expression in normal and vascularized human corneas. Cornea 24:837–844PubMedCrossRef

Title: Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
Authors: Felix Bock
Yanyan König
Friedrich Kruse
Martin Baier
Claus Cursiefen
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2008
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-007-0684-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2008

Retained large nail with perforating injury of the eye

Transplantation of cells from eye-like structures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal ganglion-like cells

Bone marrow-derived progenitor cells promote corneal wound healing following alkali injury

Comment on the recent publication “Conjunctival nodules associated with Vogt-Koyanagi-Harada disease”

Modeling the effects of aging on retinal ganglion cell density and nerve fiber layer thickness

Ocular traumatology and the ocular trauma specialist